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ABSTRACT 
 
This was a prospective hospital based study conducted in the renal 
centers of Khartoum state in the period from June 2004 to January 
2005, with the aim of evaluating the anaemia status and 
managements in Sudanese children with chronic renal failure, and 
to find out if the use of erythropoietin caused a reduction in 
frequency of blood transfusion requirements. 
Fifty three patients with ESRD or pre-ESRD were studied by 
history, examination and investigations, and then follow up for a 
period of three months, thereafter they were reassessed for  
changes in their status.  Children in the study group failed to show 
the expected increase in hemoglobin (from 7.7g/dl in ESRD) and 
haematocrit (from 23.6% in ESRD), yet the rate of decline of 
hemoglobin in EPO users was 1.5% compared to 5.5% in non-
users., Erythropoietin was administered in fixed dose of intravenous 
100 units/kg/week instead of being adjusted according to each 
patient s requirement. 
It was concluded that EPO treatment did not improve the anaemia 
of the children studied yet it played an important role in preserving 
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the haemoglobins and hematocrits of the group of  patients who 
used it.It was also found that EPO among three other factors 
proved to have a highly significant effect in reducing the mortality of 
patients, as well as blood transfusion requirements.  
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 ﻣﻠﺨﺺ اﻷﻃﺮوﺣﺔ
ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻭﺼﻔﻴﺔ ﺘﺤﻠﻴﻠﻴﺔ  ﺃﺠﺭﻴﺕ  ﻓﻲ ﻤﺭﺍﻜﺯ ﻏﺴﻴل ﺍﻟﻜﻠﻰ ﺒﻭﻻﻴﺔ ﺍﻟﺨﺭﻁﻭﻡ ﻓﻲ ﺍﻟﻔﺘﺭﺓ ﻤﺎ   
ﻭﻜﺎﻥ ﺍﻟﻬﺩﻑ ﻤﻥ ﺍﻟﺩﺭﺍﺴﺔ ﻫﻭ ﺘﻘﻴﻴﻡ ﺤﺎﻟﺔ ﻓﻘﺭ ﺍﻟﺩﻡ ﻓﻲ ﺍﻷﻁﻔﺎل  .ﻡ5002ﻡ ﻭﻴﻨﺎﻴﺭ 4002ﺒﻴﻥ ﻴﻭﻨﻴﻭ 
ﻓﻲ ﺘﻘﻠﻴل ﺍﻟﺤﻭﺠﺔ ﻟﻨﻘل  "ﺍﻹﺭﻴﺜﺭﻭﺒﻭﻴﺘﻴﻥ"ﺼﺎﺒﻴﻥ ﺒﺎﻟﻔﺸل ﺍﻟﻜﻠﻭﻱ ﺍﻟﻤﺯﻤﻥ، ﻭﺘﻘﻴﻴﻡ ﺍﻟﻌﻼﺝ ﻭﺃﺜﺭ ﺍﺴﺘﻌﻤﺎل ﺍﻟﻤ
 .ﺍﻟﺩﻡ ﺍﻟﻤﺘﻜﺭﺭ
ﻁﻔﻼﹰ ﻋﻥ ﺃ ﺨﺫ ﺍﻟﺘﺎﺭﻴﺦ ﺍﻟﻤﺭﻀﻲ ﻭﺍﻟﻜﺸﻑ ﺍﻟﻁﺒﻲ ﻭﺍﺠﺭﺍﺀ ﺍﻟﻔﺤﻭﺼﺎﺕ، ﺜﻡ  35ﺘﻤﺕ ﺍﻟﺩﺭﺍﺴﺔ ﻓﻲ   
  .ﺃﺸﻬﺭ، ﺒﻌﺩﻫﺎ ﻴﺨﻀﻌﻭﺍ ﻟﻠﻔﺤﺹ ﻤﺠﺩﺩﺍﹰ  ﻟﻠﺘﻘﻴﻴﻡ 3ﻤﺘﺎﺒﻌﺔ ﺍﻟﻤﺭﻀﻰ ﻋﻠﻰ ﻤﺩﻯ 
 ﺩﻴﺴﻠﺘﺭ/ﺠﻡ7.7ﻤﻥ  ﻟﻤﺭﻀﻰ ﻓﻲ ﻫﺫﺍ ﺍﻟﺒﺤﺙ ﻓﺸﻠﻭﺍ ﻓﻲ ﺇﻅﻬﺎﺭ ﺍﻻﺭﺘﻔﺎﻉ ﺍﻟﻤﺘﻭﻗﻊ ﻓﻲ ﻨﺴﺒﺔ ﺍﻟﻬﻴﻤﻭﻗﻠﻭﺒﻴﻥ ﺍ
، ﻭﻟﻜﻥ ﺜﺒﺕ ﻤﻥ ﺍﻟﺩﺭﺍﺴﺔ ﺃﻥ ﻻﺴﺘﻌﻤﺎل % 6.32  ﻤﻥ )TCH(ﻭﻓﻲ ﺩﻻﻟﺔ ﺍﻟﻜﺭﻴﺎﺕ ﺍﻟﺤﻤﺭﺍﺀ 
ﻓﻲ ﻤﺴﺘﻌﻤﻠﻲ  %5.1ﻋﻼﻗﺔ ﻭﻁﻴﺩﺓ ﻓﻲ ﺘﻘﻠﻴل ﻨﺴﺒﺔ ﻫﺒﻭﻁ ﺍﻟﻬﻴﻤﻭﻗﻠﻭﺒﻴﻥ ﺇﺫ ﻜﺎﻨﺕ  "ﺍﻹﺭﻴﺜﺭﻭﺒﻭﻴﺘﻴﻥ"
ﻓﻲ ﻏﻴﺭ ﺍﻟﻤﺴﺘﻌﻤﻠﻴﻥ ، ﻭﻫﺫﺍ  ﺒﺎﻟﺭﻏﻡ ﻤﻥ ﻋﺩﻡ ﺇﻋﻁﺎﺌﻪ ﺒﺎﻟﺠﺭﻋﺔ ﺃﻭ ﺍﻟﻁﺭﻴﻘﺔ  %5.5ﻥ ﻤﻘﺎﺭﻨﺔ ﺒـﺍﻟﻬﺭﻤﻭ
  .(ﺍﻻﺴﺒﻭﻉ /ﻜﻠﺠﻡ /ﻭﺤﺩﺓ )001ﺍﻟﻤﻼﺌﻤﺔ 
ﺍﻹﺭﻴﺜﺭﻭﺒﻭﻴﺘﻴﻥ ﺒﺎﻹﻀﺎﻓﺔ ﺇﻟﻰ ﺜﻼﺜﺔ ﻋﻭﺍﻤل ﺃﺨﺭﻯ ﻤﺘﻭﺍﺠﺩﺓ ﻓﻲ ﺍﻟﻤﺭﻀﻰ ﺍﻟﻤﺘﻠﻘﻴﻥ ﻟﻠﻐﺴﻴل   
 . ﻭﺍﻟﺘﻘﻠﻴل ﻤﻥ ﺍﻟﺤﻭﺠﺔ ﻟﻨﻘل ﺍﻟﺩﻡ ﺍﻟﻤﺘﻜﺭﺭﺍﻟﺩﻤﻭﻱ ﺃﺜﺒﺘﻭﺍ ﺃﻥ ﻟﻬﻡ ﺩﻻﻟﺔ ﺇﺤﺼﺎﺌﻴﺔ ﻤﺅﺜﺭﺓ ﻓﻲ ﻤﻌﺩل ﺍﻟﻭﻓﻴﺎﺕ،
ﺘﻘﻴﻴﻡ ﺤﺎﻟﺔ ﺍﻟﺤﺩﻴﺩ ﻟﻠﻤﺭﻀﻰ ﻓﻲ ﺍﻟﺒﺤﺙ ﺃﻭﻀﺤﺕ ﺃﻥ ﻨﺴﺒﺘﻪ ﻓﻲ ﺍﻟﺩﻡ ﻜﺎﻨﺕ ﻁﺒﻴﻌﻴﺔ، ﻤﻤﺎ ﻴﺭﺠﺢ ﺃﻥ ﻤﺨﺯﻭﻥ 
ﺍﻟﺤﺩﻴﺩ ﻓﻘﻲ ﺍﻟﺠﺴﻡ ﻜﺎﻥ ﻜﺎﻓﻴﺎﹰ ﺃﻭ ﺍﺤﺘﻤﺎل ﺘﻌﺎﻁﻲ ﺠﺭﻋﺎﺕ ﻋﺎﻟﻴﺔ ﻤﻥ ﺍﻟﺤﺩﻴﺩ ﻓﻲ ﻤﺭﻀﻰ ﻏﺴﻴل ﺍﻟﻜﻠﻰ 
  .ﺍﻟﺩﻤﻭﻱ
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1. INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction: 
In chronic renal failure (CRF), as renal function deteriorates, various 
clinical abnormalities related to progressive loss of renal metabolic and 
homeostatic functions appear(1), and anaemia  which affects young 
children with an estimated  prevalence of 43%(2), is almost universal in  
renal disease once renal insufficiency ensues (3) . Sudanese reference 
values for anaemia, studied by Ateig (1995), showed the mean 
haemoglobin was 11.6 g/dl +0.8 g/dl, with no statistical difference 
between males and females and an apparent increase in haemoglobin 
with increasing age. Other studies done in Sudan were mainly 
concerned with anaemia in relation to malnutrition and endemic 
diseases (4). 
Anemia is a characteristic finding in CRF. The primary cause is 
decreased production of the glycoprotein erythropoietin by the damaged 
kidney. Erythropoietin is produced by particular interstitial cells within the 
inner cortex and outer medulla(5). It now appears that the development of 
anaemia not the accumulation of ill-defined uremic toxins, is responsible 
for many of the symptoms seen in CRF. Appetite, physical activity, 
libido, school attendance in children, and in some studies, performance 
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in IQ testing , are all improved after the correction of anaemia using 
erythropoietin (6). 
Additional contributing factors include decreased blood cell survival, 
bone marrow inhibition, intestinal, and later dialysis- related blood loss, 
and Iron deficiency. In children anaemia appears when glomerular 
filtration rate (GFR) decreases to between 20 and 35mls/minute per 
1.73sq m(7,8); at lower GFRs, pre pubertal children have hemoglobin 
levels about 2 gms /dl lower than those of adults (6). 
Before the availability of recombinant human erythropoietin (r-HuEPO , 
transfusions were required in almost all children with chronic renal 
insufficiency to maintain hematocrits . This was associated with the 
development of total body Iron overload as well as increased exposure 
to human lymphocyte antigen (HLAs) and infectious agents(6). 
Although most patients report subjective improvement in appetite and 
food intake, with the use of recombinant EPO, there has been no 
improvement in weight or height standard deviation scores (SDS). The 
most common side effects associated with erythropoietin use are the 
development of Iron deficiency and an increased incidence of 
hypertension (6).    
Many renal centers in developed countries appoint a special staff 
for the task of anaemia management ; namely Anaemia or EPO 
coordinator, Anaemia nurse and if not feasible at least a designated 
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registrar. Some hospitals have also developed a computer-aided system 
for the administration of EPO and Iron( Donald Richardson. A Computer 
algorithm for the treatment of renal anaemia,2nd  National Intravenous 
Iron Day,18th of January 2000,Birmingham, Heartland Education Centre 
:p. 3) ,in accordance with  guidelines dealing  specifically with the 
management of anaemia in renal failure ( Iain Macdougall. New 
European guidelines on iron management, 2nd National Intravenous Iron 
Day,18thof January 2000,Birmingham,Heartland Education Centre :p.1) . 
Yet this should not discourage us or hinder our efforts for improving and 
generalizing it's use which proved to be well accepted by patients and 
their families, reliable ,effective ,and easy to administer in outpatient 
clinics.  
        In Sudan, erythropoietin has recently been provided by support 
groups and individuals to some renal  patients on irregular basis mostly 
and only very few patients can manage a regular supply ; the situation 
thereby mandating evaluation to bring about better utilization of these 
scarce resources ,and to improve and optimize our services in a 
scientific way.  
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1.2 Literature Review: 
The association of anaemia with chronic renal failure (CRF) was 
recognized by Richard Bright 150 years ago, though the exact 
Pathophysiology was not clear. Then, Ersler (9) was first to prove that 
erythropoietin regulates  erythropoiesis and Jacobson in 1957  proved 
that it is produced in the kidney (10). It is now clear that EPO stimulates 
terminal differentiation of committed erythroid progenitors in the bone 
marrow, increases haemoglobin synthesis, and causes marrow 
reticulocytes to shift into circulation prematurely (11).    
The isolation of the human erythropoietin gene in 1983, followed by its 
cloning and the expression of the mature glycoprotein hormone from the 
Chinese hamster ovarian cell (12) resulted in the production of sufficient 
quantities of recombinant human erythropoietin (epoetin) for clinical 
trials and subsequently, as a regular therapeutic agent. This is one of 
the major advances in the management of CRF (3).    
The erythropoietin gene is located on chromosome 7 and encodes for 
193 amino acid residue glycopeptide (13).  Erythropoietin is predominantly 
synthesized by fibroblast - like interstitial cells in the kidney (14) and  to a 
lesser extent in the liver. It’s secreted as a glycoprotein containing 165 
 5
amino acid residues and four carbohydrates side chain, with a molecular 
mass of 30,400 Daltons (15).    
          Erythropoiesis involves an ordered series of cellular 
differentiations that are controlled by specific haemopoietic growth 
factors. Erythropoietin is one of those factors involved strictly in the 
erythrocyte pathway. At the cellular level, erythropoietin acts similarly to 
other polypeptide hormones through surface receptors with presumed 
intracellular secondary messengers (NFK-K/ DOQI Clinical practice 
guidelines for anaemia of chronic kidney disease, the test substance , 
mode of action , p3). 
   The anaemia of CRF however is not a single effect of erythropoietin 
deficiency, although this is probably the major pathophysiologic 
factor(16).    
1.2.1  The pathophysiology of anaemia of chronic renal failure: 
Classically, the following mechanisms are considered in the 
pathophysiology if anaemia of CRF: 
A. Erythropoietin deficiency: 
This is the major cause of anaemia in patients with CRF(17).    The 
kidney produces 90% of  the  needed  EPO and 10%  is  from  the 
 6
liver(18).Hypoxia stimulates EPO production and normal subjects can  
increase  their EPO  levels  by 10-100  times  the  normal  (19).     
     When renal failure develop, EPO response is blunted , resulting only 
in a partial rise reaching hardly to low normal or below normal levels (20). 
However, even severely damaged kidneys can still produce small but 
significant amounts of EPO. This is clearly demonstrated by the 
worsening of anaemia that is observed in patients with End - stage renal 
failure who undergo bilateral nephrectomy (21).    
A variety of factors stimulate EPO production, many of these are 
characterized by alteration of oxygen delivery to tissues. They include 
anaemia caused by bleeding or hypofunctional bone marrow leading to 
a decrease in oxygen carrying capacity(10); a decrease in arterial PO2 
tension (Hypoxia) consequent upon cardiopulmonary disorders; and 
other factors which decrease oxygen release such as decreased 
concentration of 2-3 DPG and abnormalities in haemoglobin structure 
(21). EPO is also stimulated when oxygen requirements are increased, 
Such as, increased basal metabolic  rate  seen  in  thyrotoxicois (22).     
     Various experiments have shown that the EPO stimulating oxygen 
sensor is located in the kidney and is sensitive to the ratio of oxygen 
supply and oxygen demand(23). The exact location of this sensor is 
however not yet clear, but experiments so far have shown it to be 
 7
around proximal tubular cells or peritubular capillary endothelial cells of 
the renal cortex and outer  medulla (24).     
B. Toxic metabolites: 
Retained toxic metabolites have been postulated to be a major cause of 
anaemia for many years (25). The mechanism of action was said to be 
through blunting the effect of EPO(26) , and reducing the number of 
erythroid progenitor cells. The substances blamed for these effects were 
parathormone (PTH) (27), spermine(28),  and ribonucleasis (29).    
Current studies however indicate that these substances are unlikely to 
be a major cause of anaemia in renal failure. Moreover, anaemia rarely 
improves with the initiation of any type of dialysis (30). In vitro studies 
have indicated that purified PTH does not inhibit the growth of erythroid 
progenitor cells in the presence of EPO (31).    
Spermine is not elevated in hemodialysis patients(32), and ribonuclease 
inhibits erythroid progenitor cells only when added in large unphysiologic 
doses to the culture media . It, therefore, seems that toxic metabolites 
are unlikely to play a major role in inhibiting erythroid tissue and if they 
do, their effect can be easily overcome by the use of recombinant 
human EPO (33).     
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C. Shortened red cell survival: 
Hemolysis due to decreased red cell survival was demonstrated by 
studies using 51 Cr-labeled red cells in uremic patients (34). Neither 
hemodialysis nor peritoneal dialysis, significantly improved red cell 
survival(35-38). Hypersplenism due to chronic hepatitis, siderosis or  
marrow  fibrosis  may  contribute  to  hemolysis  (35).      
D. Blood loss  
Renal failure patients are prone to have bleeding from the   
gastrointestinal tract, mucous membrane and other sites (39). This 
bleeding is usually secondary to qualitative platelet dysfunction due to 
decreased platelet factor III activity, decreased thromboxane A2, 
increased prostacycline and sub-optimal factor VIII Von Willebrand 
Complex(40-42). Dialysis procedures and frequent investigations   also   
contribute   to  anaemia (16). 
E. Aluminum toxicity: 
Aluminum toxicity will result in hypochromic microcytic anaemia (43), and 
the differentiation from iron deficiency anaemia may be difficult. This 
entity must always be kept in mind in patients who have been on dialysis 
for many years (16).  
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F. Osteitis fibrosa cystica (Brown Tumour): 
    Severe hyperparathyroidism resulting in Osteitis fibrosa cystica may 
contribute to anaemia by obliterating the marrow space  (44). 
G. True iron deficiency anaemia: 
 True iron deficiency anaemia is not uncommon in dialysis patients  (45). 
The major cause is chronic blood loss and concomitant nutritional 
anaemias (16). 
1.2.2. Erythropoietin in the Management of Anaemia of chronic 
renal failure: 
The kidney is the primary site for erythropoietin production in adults, with 
the liver making only a minor contribution(46,47). Studies utilizing 
transgenic mice suggest that a population of interstitial fibroblasts (also 
known as type I interstitial cells) is the major source of renal 
erythropoietin synthesis. Interstitial cells positive for erythropoietin (EPO) 
messenger RNA are limited to the deep cortex and outer medulla in the 
un-stimulated kidney. With the increasing anaemia, the number of 
positive cells increases and spreads into the superficial cortex (48). 
However, the primary site of EPO production remains unresolved, since 
other transgenic studies suggest a major role for the proximal tubule 
cells (49). 
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The release of EPO is regulated via feedback mechanisms involving 
tissue oxygenation. The renal oxygen sensor is probably a heme 
protein(47,50). In the presence of decreased oxygen delivery, activation of 
this sensor appears to lead to the synthesis of a protein that binds to  
the active site on the enhancer region of the EPO gene, leading to 
increased EPO production , the ensuing rise in red cell production will 
tend to return oxygen-carrying capacity towards normal(51). 
The kidney is quite suited to be the site of EPO production because it is 
able to dissociate changes in blood flow alone from those due to 
oxygenation (48). 
 EPO has other haematological benefits which include increasing the 
platelet count and correcting the abnormality in platelet function, thereby 
lowering the bleeding time and lessening the risk of uraemic bleeding(52).  
In a study by Vinhas J; et al in 1990, changes associated with 
recombinant erythropoietin were studied in eight hemodialysis patients 
treated with EPO. Results showed that EPO did not induce any change 
in number of platelets, but seemed to improve platelet function as shown 
by the percentage of aggregation with ADP and coagulation activities(53). 
Further studies in 2002-2003 by Zhou; et al, revealed that improved 
calcium signaling in uremic platelets with chronic erythropoietin therapy 
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is the biochemical basis of the previously reported platelets dysfunction 
and prolonged bleeding time (54).  
Via uncertain mechanisms, EPO appears to have additional beneficial 
actions:  
(1) Relief of a variety of uremic signs and symptoms such as pruritis, 
sexual dysfunction in men and impaired carbohydrates and cortisol   
metabolism(55). 
(2) Improved quality of life parameters particularly vitality and sleep 
(56,57). In a single blind placebo controlled study by Morris KP; et al 
1993 about non cardiac benefits of human recombinant 
erythropoietin, eleven  children with end stage renal disease were 
assessed for the clinical benefits resulting from correction of 
anaemia. Subcutaneous administration of r-HuEPO twice a week 
resulted in an increase in haemoglobin concentration from 73 to 112 
g/L. this was associated with an objective improvement in physical 
performance and health and better school attendance (58).  
(3) Successful treatment of anaemia has profound effects on the 
cardiovascular and haemodynamic abnormalities that accompany 
end stage renal disease(ESRD) (59).    
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Table (1): Symptoms and signs in CRF improved with partial or 
complete correction of anaemia (3): 
Non-Cardiac symptoms (signs) Cardiac symptoms (signs) 
Quality o life Reduction in cardiac output 
Maximal exercise capacity Reduction in left ventricular 
dilatation and hypertrophy 
Cognitive function, nocturnal penile 
tumescence 
Reduction in angina, if present 
Resumption of menses  
Immune responsiveness  
Sleep patterns  
Decreased uremic bleeding 
tendency 
 
Studies by Lim; et al (60), Jungers (61), and in the paediatric population by 
Kramar et al (62) and Kuriyama (63), have indicated that the treatment of 
anaemia of chronic renal failure using erythropoietin may prolong the 
renal survival and lead to lower rates of progression of renal function, 
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albeit the number of the patients in the paediatric study was 11, thus no 
statistical significance could be shown(64).  
 Treatment with recombinant erythropoietin is effective before and after 
institution of dialysis(6): 
 In a study from Florida USA by Mihaly Tapolyai; et al;2003, 18 pre-
ESRF adult patients were analysed retrospectively 12 months prior, and 
prospectively 12 months after initiation of EPO. The results showed that 
treatment of the anaemia of CRF with subcutaneous erythropoietin , 
when instituted together with  vigorous metabolic control may slow the 
rate of renal function decline and in some cases may even reverse the 
process of renal function loss  (64). 
 Another study by Litwin-M; et al; 1994, was done in ten children with 
uremic anaemia on hemodialysis. During a six months follow-up, 
hematocrits and hemoglobins have been 30% and 9-10 grams/dl, 
respectively .A decrease in Iron levels and transferrin saturation were as 
well noted in all patients (65).  
 In Bulgaria , a study done by Dimitrakov et al;1994 about the effect of 
recombinant erythropoietin on renal anaemia in  adult predialysis 
patients with chronic renal failure ,showed that erythropoietin given 
subcutaneously (mean dose of 50U/kg)  in  form of Eprex ,thrice weekly 
for six months, aiming at keeping the hemoglobin in the target range of 
100 and 120 grams per Litre, has lead to an increase from a previous 
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mean baseline hemoglobin of 75.5+/-4.06 g/L  to 96.3 +/-6.9 g/L at three 
months and 106+/- 7.1 g/L at six months  (P<0.01).The baseline MCHC 
increased from 313.6 +/- 2.7 g/L to 324.3 +/- 4.29 g/L (P<0.05) during 
the third month of treatment. Hematocrit also increased significantly from 
0.23 +/- 0.01 to 0.31 +/- 0.01 (P< 0.01) during the third and to 0.36 +/- 
0.02 (P<0.001)  during the sixth month of treatment. The erythrocyte 
counts from 2.73 +/- 0.2x10(12) /I reached 3.69 +/- 0.24x10(12) /I 
(P<0.01) at three months  and 4.01 +/- 0.27x10(12) /I (P<0.001)  at six 
months. The serum iron decreased from 12 +/- 0.36 mmol /L to 10.5 +/- 
1.0 mmol /L (P<0.05)  and 0.93 +/- 0.9 mmol/L (P<0.02)  at three and six 
months, respectively  .The dose of Eprex , therefore was found to have 
a positive correlation with the hematocrit and the erythrocyte values in 
the treated patients (66). 
 In a study from UK by Rigden-SP et al;1990,  six children (aged 3 years 
11 months to 15 years 9 months) with end stage renal disease and 
anaemia (mean hemoglobin 7.1g/dl, range 6.3-7.7g/dl) on thrice weekly 
hemodialysis were treated with recombinant human erythropoietin 
(rHuEPO) . All responded with an increase in reticulocyte count and 
hemoglobin concentration in a mean time of 11 weeks .The dose of EPO 
was then adjusted to maintain the Hb within the lower half of the normal 
range for the child's age and sex. The mean hemoglobin after 12 weeks 
treatment was 10.9 g/dl (range 8.5-12.1g/dl) and after 24 weeks 10.5g/dl 
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(range7.9-13.3g/dl). Four children had no further need for blood 
transfusion and serum ferritin fell in the three patients with evidence of 
iron overload; the three with low or normal Iron stores at the onset of 
treatment maintained erythropoiesis with oral Iron supplementation .HLA 
antibodies decreased in all patients(67).                                          
In Japan, a multi-institutional study by Akizawa T et al; 1988 was done, 
about the clinical effects of recombinant human erythropoietin on 
anaemia associated with chronic renal failure ,66 hemodialysis patients 
with intractable anaemia were treated with intravenous human 
erythropoietin in a dose of 50 units /kg dry weight period of four weeks  
,then the dose was increased to 100 and 200 units /kg dry weight for 
poor responders.   The patients' hematocrits rose from19.8+/-2.3% ( pre 
-treatment )to 30.3+/-4.9% after twelve weeks .From 206 units of blood 
transfusion requirement in the three months period before the study , 
only 34 units were needed after treatment. Serum iron and ferritin levels 
fell significantly during the study and iron storage was considered to be 
one of the decisive factors in the response to recombinant human 
erythropoietin(68).   
 In an open –label multicenter study of (r-HuEPO) by Van-Damme 
Lombaerts-R, et al; 1994, 116 children aged 6 months to 20 years with 
anaemia of CRF undergoing haemodialysis were studied. Haemoglobin 
concentrations at entry ranged from 3.4-9.5g/dl .Recombinant human 
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EPO was given intravenously two or three times per week, the starting 
dose being 75 units /Kg per week. This was subsequently titrated in 
steps of 75 units /kg per week with the goal of increasing hemoglobin 
concentration at a rate of one gram/dl per four weeks into the range of 
9.6 - 11.2 grams/dl( 6-7mmol/l ).Treatment was continued for one year 
with the aim of maintaining the hemoglobin concentration within the 
target range . Of the 115 children in whom efficacy could be evaluated, 
93( 81% ) achieved the target hemoglobin and a further six had a rise in 
hemoglobin concentration of at least 2 grams/dl. At 52 weeks a median 
maintenance dose of 225 u/kg per week was given to children weighing 
less than 30 kg, compared to 107 u/kg per week for those weighing 30kg 
or more. The transfusion requirements fell from 8.9 to 0.7 units /patient 
per year (69). 
In another study by Aufricht,-c, et al; the efficacy and safety of 
subcutaneous (rHuEPO) was looked at in 25 children with chronic renal 
allograft dysfunction; 19 girls and 12 boys (mean age 15.8+/-4.2 years) 
received treatment for 9 – 162 (median 43) weeks. Recombinant human 
erythropoietin was started once weekly at a dose of 105 +/-25U/kg per 
week in 16 children, twice weekly at a dose of 175+/-70U/kg per week in 
six children , and three times weekly at a dose of 270+/-28 U/kg per 
week in three children. The hematocrit increased in 21 children from 
23.2% +/-3.1% to 33%+/-3.1% within 7.2 +/- 4.9 weeks at a mean rate of 
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1.98% per week. The increase in hematocrit proved to be linearly related 
to the starting dose of erythropoietin given (delta hematocrit / week =0.8 
+ 0.08 U /kg per week, r=0.44, P<0.05) .The maintenance dose 75 +/-
23(43-114) U/kg per week. .Results showed that subcutaneous rHuEPO 
at a single weekly dose of 100 U /kg per week is highly effective in 
children with chronic graft dysfunction. Four patients failed to reach the 
target Hemoglobin most likely because of none compliance(70). 
1.2.3 Erythropoietin and iron balance in end stage renal disease: 
Adequate iron stores are essential for achieving maximum benefits from 
erythropoietin. Decreased iron stores or decreased availability of iron is 
the most common reason for resistance to the effect of erythropoietin71). 
The non-transfused dialysis patient is in a state of continuous iron loss 
from gastrointestinal bleeding, blood drawing and most importantly, 
dialysis treatment itself. Hemodialysis patient lose an average of 2 
grams of iron per year, thus iron deficiency will develop in all patients 
receiving erythropoietin unless supplemental iron therapy is given orally 
or intravenously(72).The use of intraperitoneal iron dextran in peritoneal 
dialysis patients receiving erythropoietin , was also evaluated by Mars 
RL et al. Results proved it to be a safe and effective route of iron 
administration(73). 
Anaemic patients undergoing dialysis may have suboptimal responses 
to oral iron therapy, under basic conditions, their absorption level of iron 
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and therapeutic oral iron are similar to levels in normal subjects (74).In 
Sudan, Tammam A.1998,studied the iron status of adult hemodialysis 
patients in a case control study. Results showed no significant difference 
in the study group iron status from that of the general population(75).   
During erythropoietin therapy the absorption of ion therapy decreases as 
much as five times, nevertheless, external iron loss including loss from 
hemodialysis and blood testing exceed gastrointestinal ion absorption 
(76).Poor compliance because of gastrointestinal symptoms is 
problematic and significantly reduced iron absorption may occur with 
some newer iron formulations (77). 
Iron restricted erythropoiesis is evident by chemical responses to 
ascorbate supplementation, thought to facilitate the release of ion of 
reticuloendothelial stores and increase iron use by erythrons (78), and by 
the success of intravenous iron therapy in reducing erythropoietin 
dosage(79). 
In a study by Pela-I. et al, 1991; about the influence of iron metabolism 
on the efficacy of r-HuEPO treatment of anaemia in children on 
hemodialysis; of the five children studied, two were noticed to have 
significant reduction of hematic activity, whereas, 3 showed iron 
deficiency characterized by a reduced percentage of total transferrin 
saturation in the plasma, in the presence of high ferritin in the blood. 
Also discovered was a missing increase or even a fall of hemoglobin 
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values obtained. In these cases, the increase of the hormone dose did 
not lead to an improvement of iron. The author in conclusion affirmed 
that iron deficiency is the first cause to be researched and corrected for 
the missing increase in hemoglobin despite adequate EPO dosing (78). 
A reduction in plasma ferritin can be expected during the first few 
months after the initiation of  EPO as iron is mobilized from iron stores 
and used for red cell production .Ferritin is also an acute phase reactant, 
with plasma levels rising in inflammatory stages, thus a falling plasma 
iron and transferrin saturation coupled with rising plasma ferritin may 
indicate iron deficiency in the presence of inflammation (80). 
An important issue in diagnosis of iron deficiency in the patient with end 
stage renal disease is that the laboratory criteria are somewhat different 
from those in patients with relatively normal renal function. Iron 
deficiency is probably present in end stage renal disease when the 
transferrin saturation falls below 20% or the plasma ferritin concentration 
is less than 100 ng/ml(81). However, the latter value is within the normal 
range in normal subjects. When an otherwise normal person develops 
anaemia due to iron deficiency, the plasma ferritin should be below 10 
ng/ml. The discrepancy between subjects with normal function and 
those with end stage renal disease with respect to the plasma ferritin 
concentration may reflect an underlying inflammatory state associated 
with advanced renal failure and dialysis (82-86), the analysis of C-reactive 
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protein is useful in ruling out an inflammatory   process (Valderrababuo F.The 
optimal treatment of anaemia in ESRD,2nd ERA-EDTA training course:1998June5-6;Madrid-Spain;p49-53)  
 The best marker for iron deficiency is the percentage of hypochromic 
red blood cells. This parameter, proposed by Mac Dougal, is suggestive 
of iron deficiency when more than 10% of red blood cell show a 
hemoglobin concentration lower than 28 pg. Blood red cell ferritin 
concentration shows a better correlation to iron stores than serum 
ferritin, however, this technique is not available in the majority of 
laboratories as is the case with blood concentration of transferrin 
receptors and blood red cell free protoporphorin. Recently, the 
reticulocyte hemoglobin concentration has been proposed as an 
excellent indices of iron deficiency in end stage renal disease patients 
(Valderrababuo F.The optimal treatment of anaemia in ESRD,2nd ERA-EDTA training course:1998June5-
6;Madrid-Spain;p49-53).  
If pre-EPO iron indices indicate iron deficiency, then initiation of EPO 
should be delayed until the effect of iron replacement on erythrpoiesis 
can be ascertained. Repletion of iron stores alone, will raise the target in 
a significant proportion of patients. Furthermore, EPO administration in 
the presence of iron deficiency will be ineffective and is economically 
unsound (86).  
All dialysis patients should receive supplemental iron, except for those 
with excessive iron stores (as evidenced by plasma ferritin concentration 
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above 800 ng/ml and / or a transferrin saturation above 50%).  
Continued iron therapy in such patients may result in iron toxicity (NKF- 
DOQI guidelines III: Iron support :guidelines 5-10:Part 1) (86). 
A study in King Fahad General Hospital, Jeddah by F.A.M Shaheen et 
al, 1990; about the iron status in haemodialysis patients, was conducted 
. Investigations were performed to find out the need for iron 
supplementation , and to test if there was any correlation between 
microcytic anaemia with a corresponding serum ferritin level, showed 
that all 53 adult patients showed evidence of anaemia, and in 14 (26%) 
patients the anemia was due to  iron deficiency. In three, the iron 
deficiency had already progressed to the stage where low MCVs were 
present. In the other 11 patients, low ferritin levels i.e depleted iron 
stores, were not accompanied by changes in the hemogram. The serum 
iron levels were low in 29 (54.7%) patients, and the serum transferrin 
levels were low in 23 (43.4%) patients. Both these results did not 
correlate well with the status of the body iron stores as measured by the 
serum ferritin levels. Therefore, iron supplementation was recommended 
to only be given to selected patients on the basis of the results of ferritin 
estimation regardless of the various parameters of the hemogram (87).  
 The proper approach in the subgroup of patients with high plasma 
ferritin concentration but transferrin saturation below 20% is uncertain. 
This combination of findings is suggestive of an inability to utilize iron. In 
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some cases, the administration of iron in such patients may be toxic, as 
evidenced by significant inhibition of polymorphonuclear cell function in 
one report(88).  
 1.2.4  Investigations: 
When the hemetocrit/hemoglobin decreases to <80% of the mean 
values observed in normal subjects, the cause of the anaemia should be 
investigated. This corresponds to a hematocrit of 37% or hemoglobin 
<12 g/dl (3).   
While erythropoietin deficiency is the most likely cause of anaemia in a 
patient with serum creatinine > 2 mg/dL and a normochromic normocytic 
anaemia, it is important to rule out other potential aggravating causes of 
anaemia such as iron deficiency, hyperthyroidism, hemolysis and 
hemoglobinopathies. The minimum work up (table 3) should  consist of: 
(1) RBCs indices: (looking for microcytosis or macrocytosis). 
Macrocytosis may suggest folate or B12 deficiency, but it may also be 
observed in epoetin induced erythropoiesis in which younger 
reticulocytes are released into the circulation. Microcytosis can be 
observed in advanced iron deficiency, aluminum excess, and some 
hemoglobinopathies. In Sudan 2003 a study by Bafakeer about 
assessment of Iron status showed that all the eleven children among 
the study group had anaemia and low MCH compared to MCV and 
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MCHC.MCH proved to be a more sensitive indicator of iron deficiency 
as far as RBC indices are concerned(89).   
(2) Reticulocyte count: Usually not increased in renal failure if adjusted 
for the anaemia. 
(3) Iron tests :consisting of : 
• Serum iron 
• Total iron binding capacity (as a surrogate for transferrin). 
• Serum ferritin levels. 
(4) Tests for occult blood in the stool. 
(5) Serum erythropoietin level: Is not necessary if the serum 
creatinine is > 2mg/dL , unless the reticulocyte count is increased 
significantly (microangiopathic hemolytic anaemia will transiently 
increase serum erythropoietin levels) (3).   
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Table (3): Investigation for anaemia in chronic renal failure (3).     
Red blood cell indices 
Reticulocyte count 
Serum iron and total iron binding capacity 
Serum ferritin 
Test for stool occult blood  
  Source: Comprehensive Clinical Nephrology (3).   
 
1.2.6 Treatment of anaemia in chronic renal failure : 
1.2.6.1 Timing and goals of therapy: 
The NKF-DOQI guidelines recommend that patients with chronic kidney 
disease (CKD) with GFR<60 ml/min/1.73 m2 be monitored regularly for 
declining HCT,with a thorough investigation for non renal causes of 
anaemia if the HCT declines to <80 % of the mean level for the gender 
and age – matched population(90). 
An ideal goal may be to prevent anaemia altogether and maintain a 
hemoglobin/hematocrit level that is normal for age and gender. However 
the current targets recommended internationally are 33%-36% for 
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dialysis and predialysis patients(91,92,93).MacDougal recently reviewed 
possible strategies for treatment of anaemia related to chronic kidney 
disease (CKD).He concluded that the traditional approach of treating 
anaemia only after the initiation of renal replacement therapy with the 
goal of achieving modest Hg/HCT levels may not result in full 
improvement of the patient's cardiovascular and general health status. 
An alternative approach would be to begin therapy once Hg/HCT levels 
reach a certain threshold, with a goal of correcting to near normal levels, 
or even to institute therapy once Hg/HCT levels fall below normal. This 
latter aggressive strategy may be the most likely to ameliorate the risk or 
severity of associated complication (94).  
:1.2.6.2 Erythropoeitin: 
It has been accepted that the indication for starting treatment with 
erythropoetin is when the haematocrit is lower than 30% in a patient with 
adequate iron stores. However, the indications must be individualized, 
as well as the target haematocrit during treatment. There are also 
differences in the indications for treatment according to the age and 
physical activity of the patient (94).. 
(A) Dose of erythropoietin: 
 Starting doses of 50-100 U/kg have been studied, with higher doses 
found to be more effective among patients with hematocrit levels <30%. 
However if preventive treatment is initiated, much smaller doses may be 
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adequate. Maintenance doses and dosing frequency should be 
individualized to the patient's response (94).Saleh Aswad, et al ;conducted 
a study in ten patients in two busy  hospitals in Makkah ,for twelve 
weeks, to see if administration of a small fixed dose of erythropoietin(50 
U/kg/dose, thrice weekly) was effective. This proved to be so, and 
compared to the previous protocols using large and rapid increments ,  
posed less side effects ,allowing less worries about close monitoring(95). 
The rate of increase in hematocrit is dose dependant(3). In a study by 
Port,-R-E, et al; 1998, Predicting the time course of hemoglobin in 
children treated with erythropoietin for renal anaemia, was proved, 
hemoglobin – time data being analyzed (96). 
(B) Route of admenistration:  
Subcutaneous administration allows for lower doses to achieve and 
maintain goal Hg/HCT levels, and is the only practical method of 
administering r-HuEPO to patients with CKD(97,98). A recent meta-
analysis showed that the average weekly dose during the maintenance 
phase was 30 % lower in patients who received subcutaneous r-HuEPO 
compared with those who received it intravenously(99). When using the 
subcutaneous route, it is more comfortable for the patient to decrease 
the frequency of the injections to once or twice per week. This is also 
indicated in pre-dialysis and peritoneal dialysis patients. After 3 months 
of treatment, it is possible to decrease to a maintenance dosage, 
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variable according to the response of each patient and   target 
hematocrit (Valderrababuo F.The optimal treatment of anaemia in ESRD,2nd ERA-EDTA training 
course:1998June5-6;Madrid-Spain;p49-53).. 
In a pilot study, Braun A. et al 1993, investigated the pharmacokinetics 
of r-HuEPO applied subcutaneously to 20 paediatric patients in different 
stages of CRF. Results showed that the single dose kinetics of its use in 
CRF children is comparable to that of adult patients, due most probably 
to it's prolonged action (101). 
(C)Types of erythropoietin: 
• Erythropoietin alpha: Known as Procrit and Epogen in USA 
and as Eprex in Europe. It is only recommended for 
intravenous use because it was found to be associated with 
significant complications when given by the subcutaneous 
route ,pure red cell aplasia (PRCA) being the reason why the 
first two preparations are no longer  indicated, and Eprex which 
is not bound to Human albumen is the one used but for SC 
administration only(101).  
• Erythropoietin beta (NeoRecormon): A newer erythropoietin  
and more widely used now .It can be administered by both 
subcutaneous and intravenous routes with minimal 
complications .It has a longer half life, produces a significantly 
higher concentration and reticulocyte response(101). 
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• Darbepoetin(Arenesp):Another recombinant glycoprotein which 
appeared more recently. It contains substantially more sialic 
acid residues in its molecule, which accounts for a longer half-
life eliminationbecause it is broken down very slowly ,therefore 
the weekly dose is smaller by a factor of 800 (102).  
• Noval Erythropoiesis Stimulating Protein (NESP): A genetically 
engineered analogue of rHuEPO, has recently been evaluated. 
It's serum half life was found to be three times longer than 
intravenous r-HuEPO(103). A study  in 166 patients about the 
use of novel erythropoiesis stimulating protein (NESP) in the 
treatment of anaemia in  CRF, done by Francesco Locatelli, et 
al; 2001, concluded  that the response to treatment was almost 
the same to that with rHuEPO, despite the benefit of less 
frequent dosing when NESP is used(104). 
(D) Hyporesponsiveness to Erythropoetin: 
Hypo-responsiveness to erythropoietin treatment is a common 
phenomenon in anaemic patients undergoing chronic renal dialysis 
because of a variety of co-morbid conditions, particularly aluminium 
toxicity and iron deficiency (105).The individual response to EPO is 
different in each patient and depends on diverse factors which depress 
erythropoiesis, absolute or functional iron deficiency is the most frequent 
cause of erhythrpoetin hypo-responsiveness. Blood losses by different 
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routes should be ruled out when there is a bad response to 
erythropoetin. Hyperparathyroidism is probably the most frequent cause, 
after iron deficiency, of erythrpoetin hyporesponsiveness (Valderrababuo F.The 
optimal treatment of anaemia in ESRD,2nd ERA-EDTA training course:1998June5-6;Madrid-Spain;p49-53).. 
High levels of parathyroid hormone have a deleterious effect on bone 
marrow erythroid progenitors, can increase haemolysis and provoke 
bone marrow fibrosis. Some studies have shown a direct relation 
between the dose of epoetin needed and the percentage of osteoblastic 
bone surface. Parathyroidectomy improves the response to epoetin and 
some recent studies show that the improvement of moderate or severe 
hyperparathyroidism after intravenous calcitriol treatment improved the 
haematocrit levels in patients treated with erythropoietin (3). 
Aluminium intoxication causes microcytic anemia with a poor response 
to epoetin. Osteomalacia and dementia are exceptional nowadays. 
However, sub-clinical intoxication related to the intake of aluminium 
phosphate binders is more frequent. The diagnosis must be done with 
the desferroxamine test. Treatment with desferroxamine has been 
proven to be of significant benefit in controlling infection related to iron 
overload but not due to alluminium overload (106). 
Chronic inflammatory diseases and malignancies are a frequent cause 
of hyporesponsiveness to erythropoetin. Some infections decrease the 
availability of iron. Occult infections and chronic inflammatory diseases, 
 30
such as rheumatoid arthritis or systemic lupus erythematosus can 
decrease the response to erythropoetin, through the production of 
cytokines.  Interleukin 1, 2 and 6, as well as tumor necrosis factor alpha 
and gamma interferon have a suppressor effect on erythropoiesis. 
However, Interleukin 3, 12 and IGE I stimulate erythropoiesis. 
Chronic rejection or chronic dysfunction of the renal graft is a chronic 
inflammatory disease. In this situation, there is hypo-responsiveness to 
erythropoietin, mainly in patients treated with azathioprine. Cyclosporin 
A improves the response to epoetin. Blood and urine cultures, viral 
antibodies, reactive protein C levels, cytokines, rheumatoid factor , 
ANCA ,and  DNA antibodies are useful in the diagnosis of inflammatory 
diseases (Valderrababuo F.The optimal treatment of anaemia in ESRD,2nd ERA-EDTA training 
course:1998June5-6;Madrid-Spain;p49-53).. 
Malignancies are a frequent cause of hyporesponsiveness. Multiple 
myeloma and waldenstrom macroglobulinaemia usually produce 
significant anemia, which may improve with erythropoetin, but usually at 
high doses (107). Another cause of hypo-responsiveness is haemolysis. it 
can be antibody mediated or consecutive to hypersplenism. Thalasemia 
and sickle cell disease are a frequent cause of a poor response to 
epoetin, as a consequence of increased haemolysis, and may require 
very high doses of EPO (3). Myelodysplastic syndromes and prematurity 
also show a decreased response to epoetin. 
 31
Vitamin B 12 or folic acid deficiency may aggravate the anemia of end 
stage renal disease. It was recently shown that the need for Vitamin B12 
can be increased in these patients. Vitamin C deficiency usually 
provokes a functional iron deficiency, which improves with Vitamin C 
supplements. Severe malnutrition also interferes with erythropoetin  
(Valderrababuo F.The optimal treatment of anaemia in ESRD,2nd ERA-EDTA training course:1998June5-
6;Madrid-Spain;p49-53).. 
Controversy remains regarding the effect of ACE inhibitors which are 
used to suppress post transplant erythrocytosis but CRF patients taking 
it may have a blunted response to epoetin (3).Theophillin is an antagonist 
of adenosine and decreases the renal production of erythropoietin, but 
there is no evidence of higher erythropoetin requirements in ESRD 
patients taking theophillin. Hypothyroidism and oxalosjs are other 
causes of resistance to erythropoetin therapy. Dialysis adequacy and 
biocompatibility are associated with a better response to epoetin therapy 
(Valderrababuo F.The optimal treatment of anaemia in ESRD,2nd ERA-EDTA training course:1998June5-
6;Madrid-Spain;p49-53).. 
(E) Associated Treatment : 
Androgens can improve the response to erythropoetin. They have a 
stimulant effect on erythropoiesis and allow for the administration of low 
doses of EPO. However, they have many adverse effects on lipids, liver 
and prostate, and, in general, their use is not recommended. Folic acid 
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has been used associated with erythropoietin, with no conclusive 
results. The improvement of dialysis efficiency and biocompatibility may 
allow for a better response to epoetin. The same is true for the control of 
hyperparathyroidism. Vitamin D metabolites are indicated for this 
purpose, as well as to provide active 1,25-dihydrovitamin D3 (calcitriol), 
production of which is affected by failure of renal activation of 25-
hydroxyvitamin D3(102). Physical exercise has also been shown to be 
beneficial, and finally, several studies are being carried out to learn 
whether or not carnitin supplementation is a good adjuvant therapy. 
(F) The cost of erythropoietin treatment in CRF: 
Many studies were done to determine the approximate cost of 
erythropoietin treatment .Durand Zaleski I; et al,1993 studied the cost of 
treating French predialysis patients with r-HuEPO ,using retrospective 
data. He arrived at an estimated cost of 2.2 and 6.5 million Swiss franks, 
or 50,000 to 140,000 Swiss franks per million population, using r-HuEPO 
dosage from 50-150 IU/kg /week (108). 
Studies about the cost effectiveness of using subcutaneous versus 
venous erythropoietin show that this brings about a 30% annual cost 
reduction (US $1761 ($1080 per patient) ,however this is not the case 
with darbepoetin alfa, which shows similar efficacy whether given SC or 
IV at the same weekly frequency (101). 
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Park L, and associates, 1998, studied the efficacy of using Iron dextran 
in hemodialysis patients receiving EPO. Econo-analysis showed that 
approximately 580 Dollars per patient per year could be saved by using 
intravenous iron dextran regimen in the iron deficient hemodialysis 
population receiving EPO, thereby reducing EPO use (109). 
1.2.6.3 Red blood cell transfusion: 
One of the goals of erythropoietin therapy is to eliminate the need for 
blood transfusion in the patient with CRF. This goal has yet to be met, 
although the number of blood transfusions is much less than in the pre-
erythropoietin era. There are several reasons why this goal has not been 
achieved .Before the use of erythropoietin, patients could stabilize their 
hematocrit / hemoglobin levels in the range 20-28%/ 7-9 g/dl by avoiding 
the erythroid suppression from RBC transfusions. Since patients have 
benefited so much from a rise in hematocrit/ hemoglobin to above 30% 
/10g/dl with erythropoietin ,transfusions are now ordered for levels of 
RBC mass higher than  observed in pre-erythropoietin era and many 
nephrologists unfamiliar with that earlier period do not realize that 
patients can tolerate lower hematocrit/ hemoglobin levels . Another 
reason is that the target hematocrit / hemoglobin is too low at 33-36% 
/11-12g/dl to allow tolerance of acute blood loss. Blood loss that a non 
anaemic patient might easily tolerate (i.e. a fall in hematocrit from 42-
32%), or a similar decline related to infection would not be treated by 
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transfusion, whereas  a similar fall in hematocrit in the patient with CRF 
whose hematocrit is 33%on erythropoietin therapy would result in a 
hematocrit of 25% and transfusion of several units of RBCs(3). The 
American College of Physicians state that the clinician should determine 
which symptoms and signs are likely to be reversed by giving 
transfusions. If none can be identified, do not transfuse (110). 
 
1.2.7 International best practice guidelines for renal anaemia 
management (Francisco Locatelli, Conference in Best Practice 
Anaemia management, Barcelona, June 2003): 
• Europe: European Best Practice Guidelines (EBPG) 
? first published in 1999 
? updated in 2000 
? new version due in May 2004 
• USA: National Kidney Foundation (NKF) Dialysis Outcomes 
Quality Initiative (NKF-DOQI) 
? first published in 1997 
? updated to NKF/Kidney Disease Outcomes Quality Initiative 
(NKF-K/DOQI), published in 2001 
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Table (4) Similarities and differences in work up 
  EBPG NKF-K/DOQI 
Work up 
<11 g/dl  
(pre-menopausal women, 
pre-pubertal patients) 
<12 g/dl  
(men, post-menopausal 
women) 
<11 g/dl  
(pre-menopausal 
women, pre-pubertal 
patients) 
<12 g/dl  
(men, post-
menopausal women) 
Anaemia in chronic 
renal failure (CRF) if: 
GFR <30 ml/min  
(no diabetes) 
GFR <45 ml/min  
(diabetes) 
Serum creatinine  
≥2 mg/dl 
              
? EBPG based on GFR 
? NKF-K/DOQI based on serum creatinine 
Table (5) Similarities and differences in Hb targets 
  EBPG NKF-
K/DOQI 
Target Hb levels >11 g/dl* 
(no upper 
limit) 
11–12 g/dl 
Cardiovascular disease (CVD) 
Sickle cell homozygote 
Diabetes, chronic hypoxaemic pulmonary 
disease 
11–12 g/dl 
7–9 g/dl 
11–12 g/dl 
  
 
? EBPG recommend individual targets 
? NKF-K/DOQI recommend a single range for all patients 
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Other international guidelines vary in target Hb levels: 
? British Renal Association >10 g/dl 
? Canadian Society of Nephrology 11–12 g/dl 
? Health Care and Financing Association 10.3–12.0 g/dl 
? Caring for Australians with Renal Impairment >12 g/dl for 
≥85% of patient.  
Table (6) Similarities and differences in erythropoietin use 
  EBPG NKF-
K/DOQI 
Recommended 
start dose of 
epoetin 
50–150 
IU/kg/wk 
80–120 
IU/kg/wk SC 
120–180 
IU/kg/wk IV 
Preferred route 
of 
administration 
SC SC 
Sufficient iron 
stores 
Serum 
ferritin  
≥100 (g/l 
TSAT 
>20% 
HRC 
<10% 
Serum 
ferritin  
≥100 (g/l 
TSAT >20% 
Dose 
indicating an 
inadequate 
response 
300 
IU/kg/wk 
300 IU/kg/wk 
SC 
450 IU/kg/wk 
IV 
 
Both sets of guidelines recommend SC administration of epoetin, 
wherever possible, the exception is epoetin alfa (Eprex), which is 
contraindicated for SC administration. 
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NKF-K/DOQI takes into account the route of administration when 
recommending starting doses and indicating a dose for an inadequate 
response. 
JUSTIFICATION 
 
• Anaemia is almost universal in chronic renal failure and its 
management is a major challenge that should be met to prevent 
the grave consequences which include rapid progression to end 
stage renal disease. 
• Erythropoietin has recently been introduced to some Sudanese 
children with chronic renal failure and end stage renal disease; yet 
no studies have been conducted to evaluate it's effects. 
• Most children with chronic renal failure are being treated for their 
anaemia with repeated blood transfusions; a modality which may 
cause many complications including rejection of renal transplants 
in the future. Introduction of erythropoietin should enable us to 
reduce or even to eliminate the need for blood transfusions. 
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OBJECTIVES 
 
• To evaluate the effect of erythropoietin in the management of 
anaemia in chronic renal failure paediatric patients who attend the 
renal units of Khartoum state. 
 
• To evaluate and assess the frequency of, and need for blood 
transfusions in managing the anaemia of those patients not 
receiving erythropoietin as compared to those receiving it. 
 
• To review treatment modalities employed for the management of 
anaemia in chronic renal failure, and compare them to the 
standard international guidelines. 
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2. PATIENTS AND METHODS: 
 
2.1 Nature of the study: 
An observational, prospective study. 
2.2 Study area:  
 The study was conducted at the following hospitals and renal centers in 
Khartoum state: 
2.2.1 Dr. Selma dialysis and kidney transplantation center:  
Established in 1985 as a referral center for patients with kidney diseases 
The pediatric division was established on 2002, renamed after the late 
prof. Selma, may God rest her soul. It is affiliated with the faculty of 
Medicine- University of Khartoum, and consists of 20 hemodialysis 
machines .It offers services for around fourteen regular hemodialysis 
children and many more in the outpatient clinic. 
2.2.2 Dialysis unit Khartoum teaching hospital: 
Equiped with 15 hemodialysis machines, only three children are enrolled 
for hemodialysis. It mainly offers peritoneal dialysis to paediatric patients   
2.2.3 Bahri renal center: 
Located inside Khartoum north teaching hospital, it was established in 
May 2003, equipped with 10 hemodialysis machines, and offers regular 
hemodialysis services for over 15 pediatric  patients. 
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2.2.4 Ahmed Gasim renal center: 
Only one paediatric patient is enrolled for hemodialysis. 
2.2.5 The military hospital dialysis center: 
Offers peritoneal dialysis for many patients. Equipped with hemodialysis  
machines, only one paediatric patient was enrolled during the  study 
period. 
2.2.6 Soba renal unit: 
With the opening of the new hemodialysis center, it promises to be a 
great help to the paediatric patients .Currently it is offering peritoneal 
dialysis with a limited capacity. 
2.2.7 The paediatric inpatient wards and out patient clinics of:  
o Soba University hospital. 
– Khartoum teaching hospital. 
– Khartoum-north teaching hospital. 
– 0mdurman children emergency hospital. 
– Ahmed Gasim hospital. 
– Gaafar Ibn Auf children emergency hospital. 
2.3 Duration of the study: 
  The study was conducted during the period between May 2004 and 
January 2005 with the data collected over a period of seven months ; 
following  the time-frame. 
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2.4 Study population: 
All children up to 18 years having chronic renal failure or end stage renal 
disease, whether on renal replacement therapy or conservative medical 
treatment. 
2.5 Case definitions: 
2.5.1 Chronic renal failure: 
 Patients in the study were classified as: 
 Mild renal failure: GFR 50-75 ml/min/1.73m².) 
Moderate renal failure: GFR 25-50 ml/min/1.75m21.73m².) 
Severe renal failure: GFR 10-25 ml/min/1.73m².) 
End stage renal disease (ESRD): GFR<10 ml/min/1.73m².)  (111) 
The patients in the study will be divided accordingly into two groups : the 
group of patients classified as ESRD, for whom renal replacement 
therapy (RRT) is required, and the second group labeled as Pre – ESRD 
which includes the rest of the patients( with GFRs >10 ml/min/1.73m²) , 
for whom RRT (either dialysis or transplantation) is not mandated. 
2.5.2 Anaemia: 
As proposed by the WHO, a child in this study was considered to be 
anaemic if: Hb<11 grams/dl (112) 
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2.6 Sampling: 
2.6.1 Inclusion criteria: 
All children up to18 years, with CRF and who are anaemic; after taking 
consent from parents or guardians. 
2.6.2 Exclusion criteria: 
Those denying consent, and patients with advanced renal 
osteodystrophy (information obtained from clinical history suggestive of 
the condition) were excluded. 
2.6.3 Sample size:  
Being a total coverage sample, all patients presenting to the study area 
and fulfilling the criteria for inclusion, in the period between June 2004 
and December 2004 were included. The total number of patients was 53 
after excluding the deceased.   
2.7 Research tools and methodology: 
Research tools included: 
• Questionnaire. 
• Physical examination including anthropometric measurements. 
• A sheet attached to the back of each questionnaire. 
• Laboratory investigations. 
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2.7.1 Questionnaire:  
Designed for data collection ,and to ensure eligibility for the study; it 
contained personal details ,relevant social ,past, family, nutritional 
histories , and details about his/her current condition which covered : 
time of diagnosis, symptoms and signs, relevant examination, 
treatments including dialysis ,erythropoietin and iron supplementations, 
Also details were taken  about blood transfusions given since being 
diagnosed, during the study period and since introduction of 
erythropoietin in those who received it weather on regular or irregular 
basis. 
The questionnaire was filled by the author herself for all patients.  
The investigations were done for all study group (Annex 1). 
3.7.2 Physical examination: 
Was performed by the author herself with emphasis on signs of renal 
failure and anaemia. 
 Anthropometric measurements were done as follows: 
• Weight: All children were weighed on a standing weighing scale   
measuring in kilograms. In dialysis patients the pre-dialysis 
weight was taken (dry weight).  
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• Height: Using a non stretchable tape, the height was measured 
for all children in the erect position with the heels touching the 
wall against which he/she stood.  
• Children's growth was determined using the international 
standards for weight and height (NCHS-standards) specific 
reference standards, as recommended by the WHO. Indices of 
height for age and weight for age were constructed and the Z-
scores  (calculated using the cut off points)were considered as: 
normal when Z-score is more than one standard deviation (SD), 
moderate when less than -2.99 SD  
• Severe when less than -3 SD(113) (Annex 1). 
2.7.3 Follow up sheet (appendix): 
This was designed to show patient's serial numbers, results of 
investigations and the calculated parameters; at Zero time, and three 
months later (End time)(Annex 11). The following calculated parameters 
were used: 
• GFR:  
The estimated GFR was calculated for all children at the time of 
enrollment in the study .In stable patient maintained on pre-dialysis 
treatment, the serum creatinine done on the same day of follow up visit 
was used to calculate the GFR, while in ESRD patients, serum 
creatinine done immediately before dialysis was used to calculate the 
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GFR which was calculated  using ” the Schwartz formula "for simple 
estimation of GFR in children: 
         GFR (ml/min/1.73m²) = 0.55 x L (cm)/serum creatinine (mg/dl)(114), 
where L stands for length in centimeters. 
The patients in the study will be classified as 
 ESRD: (GFR<10ml/min/1.73m².) where renal replacement therapy 
(RRT) is required . 
Pre – ESRD: (GFRs >10 ml/min/1.73m².) where RRT is not mandatory.   
• Transferrin  saturation (TSAT) :  
Was calculated for each patient following the formula below: 
TSAT = Serum iron / Total iron binding capacity x 100. 
2.7.4 Investigations: 
The following investigations were done for each child: 
(A) Hematological tests: 
5 ml of venous blood was obtained via a venous puncture, using 
vacuette sterile needles for patients not on hemodialysis. Regular sterile 
syringes were used in selected patients in whom the vacu-suction 
technique was unsuccessful or predicted to be difficult. For hemodialysis 
patients blood samples were taken just before commencing dialysis from 
the fistula site (to minimize punctures) and prior to being connected to 
the hemodialysis machine (heparin was run after samples were taken). 
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Blood was momentarily drawn into 5 ml EDTA (ethylene diamine tetra 
acetic acid) containers and taken to the lab within 1-6 hours during 
which time it was kept in a reasonably cool temperature. Results were 
thereafter obtained using a Sysmex -21 automated colorimeter, 
repeatedly calibrated to ensure quality control. By this   method 18 
haematological   parameters were produced; Hemoglobin (Hb) and 
hematocrit (Hct) being the most important for this study. 
(B) Iron studies : 
Clotted samples were obtained from venous blood which was drawn into 
4ml or 2 ml clot activator containers. These samples were further 
centrifuged, separated into plain containers and refrigerated in -20 
degrees.  The following investigations were performed thereafter: 
• Serum iron level.  
• Total iron binding capacity (TIBC). 
Each of these investigations was done by Photometric Colorimetric Test 
with Lipid Clearing Factor (Which clears turbidity caused by lipaemic 
specimens during incubation), the method using its own specific kit from 
"Human" to detect the " End point". Quality control was ensured by 
proper calibration, and by use of control sera from the same source i.e. 
Humatrol quality control serum.  
For determination of TIBC, the iron-binding transferring in serums 
saturated upon treatment with an excess of Fe ions. Unbound (excess) 
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iron is adsorbed onto aluminium oxide and precipitated. The transferring 
bound iron (TIBC) in the supernatant is then determined. To calculate 
TIBC we multiplied the result of the iron determination in the supernatant 
by the diluent factor 3 i.e.TIBC=C (iron)x3 (derived from the 
manufacturer's manual). 
2.8 Statistical analysis: 
The data were analyzed using SPSS (Statistical Package for Social 
Science computerized program). 
For anthropometric measurement determination EPI-INFO-WHO 
computer program was being used  
Multiple discriminate analysis (MDA) which is a variant of multiple 
variant analysis was used :  
1. To investigate differences among groups.  
2.  And to determine the most parsimonious way to distinguish among 
groups (117). 
2.9 Research team: 
• Researcher herself. 
• Lab technicians. 
• Statistician. 
2.10 Ethical considerations: 
• An informed verbal consent was taken from each dialysis center 
and health provider. 
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• Consent was obtained from parents or guardians  and when 
appropriate from older patients themselves , after explaining the 
purpose of the study , the tools used ,and the duration of the study 
to ensure their participation  in the later part of the study.         
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3. RESULTS 
 
During the period from June 2004 to January 2005, 53 patients with chronic 
renal failure were studied, 14 (26.4 %) of whom were categorized as having 
pre-End stage renal failure and 39(73.6%) had End stage renal disease. 
3.1 Demographic characteristics: 
3.1.1 Age and gender: 
The mean age of the study group was found to be 11.5 +/-4.1 SD (range 
1.5 -18 yrs), with a mode of 13.The age distribution of the study group is 
shown in Table (6). 
Male patients constituted 41(77.4%) of the study population, while females 
constituted 12(22.6%). The distribution by gender is shown in Figure (1).  
3.1.3 Distribution of the patients by origin: 
Of the whole population studied, 27(50.9%) originated from the Central 
region, followed in frequency by those from the North .The least frequency 
in the study group was 2(3.8%) was from the Eastern region. 
The distribution of the patients in the study group according to the origin is 
shown in Figure (2). 
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Table (6) Age distribution of the study group:   
Age group(years) Frequency Percentage 
1-<5 03 05.7% 
5-<10 12 22.6% 
10-18 38 71.7% 
Total 53 100% 
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Figure (1): Distribution of the patients by gender              n = 53 
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Figure (2): Distribution of the patients by origin                            n = 53 
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3.1.4 Family, Social and financial backgrounds: 
The majority of 45(84.9%) of the children in the study belonged to income 
privileged families while only one(1.9%) child's family was considered to be 
of high economic status .Figure (3) shows this distribution of the group by 
socioeconomic status. 
3.1.5 Availability of a parent as a provider for the family: 
Forty five children (84.9%) of the study population had a father who is the 
provider, while in 8 families the father was dead. 
3.1.6 Paternal level of education: 
Among the 45 (84.9 %) fathers of the children who are alive, eighteen 
(34%) were illiterate.  Only one parent (1.9 %) received a postgraduate 
level of education.  
Figure (4): The paternal level of education in the study group 
3.2 Characteristics of renal failure in the study group: 
3.2.1 Distribution of the group according to the type of renal failure: 
The majority 39 (73.6%), of the group were ESRD. Figure (5). The mean 
GFR of study group was found to be (11.01ml/min ± 5.9 SD). 
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Figure (3):The distribution of the study group by socioeconomic status      n = 53 
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Figure (4): The paternal level of education in the study group   n = 53 
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3.2.2 The growth parameters of the study group: 
Weight and height for age were both significantly affected as shown by 
mean Z- Scores for the studied group being < - 2.99 SD (Moderately 
malnourished), Table (7) 
3.2.3 History of blood transfusions in the study group:  
Forty patient (75.5%) received blood transfusions, Figure (6). 
3.2.5 Dialysis undertaken by the study group: 
Forty one patients (77.4 %) were dialyzed during their illness, Twenty three 
(56.1 %) of whom were undergoing hemodialysis, and the remaining 
eighteen (43.9 %) undertook peritoneal dialysis. This is shown in Figure (7). 
3.3. Characteristics of Anaemia in the study group: 
3.3.1 Prevalence of anaemia within the study group:  
Anaemia was found in all patients, with a mean Hb of(7.8g/dl ± 2.1SD) 
3.3.2 History of blood loss in the study group: 
Blood loss was found in 19(35.8%) patients and the commonest cause of 
blood loss was epistaxis 15(79.9%) while malena was the least reported, 
Blood loss was found to be dialysis –related in two patients (10.5%). 
 
 
58 
 
 
 
 
Table (7) shows the growth parameters for the study group: 
 
Parameter  -Z score for mean for age 
Wt for Age  - 2.4 ± 1.2 
Ht for Age - 2.1 ± 2.1  
Wt for Ht - 1.6 ± 1.9 
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Figure (7): The type of dialysis in the study group 
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3.3.3 Use of erythropoietin by the study group: 
Erythropoietin was used by 29 (54.7 %) patients, three (10.3 %)of whom 
were pre-end stage, and the majority of 26(89.7 %) who used it were 
ESRD. Of the whole group which used erythropoietin only 13(44.8 %) 
received it on regular basis during the study period, the remaining 16 (55.2 
%) received EPO irregularly, either due to financial or medical reasons. 
All patients who received EPO during the study period were given the same 
fixed dose of 50 U/kg of Eprex by the intravenous route. 
3.3.4 Use of iron and iron-rich foods by the study group: 
Iron was received orally in nineteen patients (35.8 %), while intravenous 
iron in form of iron dextran was received by patients on hemodialysis 
mainly,and those constituted twenty one of the whole study group(40.4 %). 
Consumption of iron rich foods which was perceived as reasonable was 
taken by twenty six (49.1 %) of the patients, while twenty seven patients 
(50.9 %) did not eat them, some because of financial reasons, and others 
due to wrong food-varieties preferences or poor appetite. 
3.3.5 Clinical manifestations of anaemia in the study group:  
Tables (8 and 9) show some of the clinical manifestations of anaemia in the 
study group.  
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Table (8) showing symptoms among the study group suggestive of anemia. 
                                  n =53 
Symptom  Frequency          Percentage 
Fatigability 44 83.0% 
Anorexia 42 79.2% 
Loss of weight 29 54.7% 
Blood loss 19 35.8% 
Skin rash 11 20.8% 
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Table (9) showing clinical signs of anaemia among the study group: 
                                            n = 53 
Sign Frequency Percentage 
Tachycardia 20 37.7% 
Palor 50 94.3% 
Nail change 03 05.7% 
Cardiomegally 03 05.7% 
Hemic murmur 08 15.1% 
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The commonest symptom reported by the majority of 44 patients, was 
fatigability (83%) followed by anorexia and the least reported symptom was 
skin rash; in 11 (20.8%). 
The commonest clinical sign among the study group was pallor in fifty 
(94.3%), followed by tachycardia and nail changes. Cardiomegally and nail 
changes were the least signs found in the studied children.  
3.4 Investigations:  
3..1 Investigations for evaluation of anaemia in the patients: 
In a total of fifty three patients investigated at commencement of the study, 
the mean haemoglobin was found to be 7.8 g/dl ±1.6 SD, and the mean 
hematocrit was 23 ±6.4 for the same group. 
At the second phase of the study, in the 39 patients for whom 
investigations were carried out, the mean haemoglobin was found to be 7.9 
g/dl ±1.6 SD, and the mean hematocrit was found to be 24.2 % ±5.1.These 
values together with other hematological parameters are shown in 
Table(10). 
The mean MCV was found to be 80.7 fL ± 12.8 at zero-time and 80.2 fl ± 
5.8 three months later( End-time.) 
 The mean MCH was found to be 27.2 ± 2.5 pg at zero time and 28.2 pg ± 
2.7 at end time. 
The mean MCHC was found to be 32.8 ± 1.5 g/dL at zero time and 32.4 
g/dL ± 1.4 at End-time. 
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Table (10): The haematological values for the patients seen at initial, 
and end time:  
Time 
Investigation 
Zero time (n=53) End time (n=39) 
Hb (g/dL) 07.8±2.1 07.9±1.6 
HCT (%) 23.8±6.4 24.2±5.1 
MCV (fL) 80.7±12.8 80.2±5.8 
MCH(pg) 
 
27.2±2.5 28.2 ± 2.7 
MCHC(g/dL) 32.8±1.5 32.4±1.4 
WBC x103/µL 7.23±3.6 06.7±3.2 
Platelets x103/µL 241 ±121 239±122 
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The mean WBC was found to be 7.239 x103/µL ± 3.57 at zero time and 
6.67 x103/µL ± 3.29 at end time. 
The mean platelet count at zero time was found to be 241 x103/µL ± 121 
and 239 x103/µL ± 122 at end time. 
All the above mentioned parameters are shown in Table (10) 
Red Blood Cells indices abnormalities: 
At zero time, 31 patients showed abnormality in only one RBC indices, 17 
showed twos, four had no change and only one patients showed changes 
in all three RBC indices (MCH, MCV and MCHC), MCH was reduced 48 
patients (90.5%), MCV was reduced in 11 patients (20.8%), while MCHC 
was the least to be affected in 6 patients (11.3%) Figure (8). 
3.4.2 Evaluation of the effect of erythropoietin on the haematological 
parameters: 
Pre-ESRD and ESRD patients from whom investigations were obtained 
completely in zero time and end time were used for the evaluation of 
treatment of erythropoietin.  
Their total number was thirty nine patients; twenty five (71.4 %) ESRD, and 
only four (11.4 %) patients were pre-ESRD.  
? Haemoglobin status and the rate of change at end time in EPO 
users and none users in ESRD patients: 
From a total of thirty five ESRD child, twenty five used EPO and showed a 
mean Hb of 7.748 g/dl ±2.2 SD at zero time and 7.628  
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g/dl ±1.3 SD at end time (P=0.766), while ten patients did not use EPO and 
showed a mean Hb of 8.61 g/dl ±1.7 at Zero-time and 8.13 g/dl ±2.3 SD at 
End-time (P=0.658). The coefficient of variation (CV) for the EPO users 
was 28.46 at time 1, and 17.27 at time 2 respectively (the 
correlation=0.454), while that for the EPO none users was 19.98, and 27.9 
at time 1 and two respectively (the correlation=0.289). Figure (9) shows the 
difference in Hb status at Zero-time and End-time in EPO and none EPO 
user ESRD patients. 
The rate of decline of Hb was calculated to be 1.54 % and 5.57 % in the 
EPO users and none users respectively. 
? Haemoglobin status and the rate of change at end time in EPO 
users and none users in pre-ESRD patients: 
Among a number of four patients with pre-ESRD only one patient used 
EPO and showed a Hb of 8 g/dl at zero time and 10 g/dl at  
end time, while three patients didn't use EPO and had a mean Hb of 7.87 
g/ dl ±1.72 SD at zero time and 9.33 g/ dl ± 0.37 SD at end time (P=1.99). 
Table (11) shows the Hb status in pre-ESRD patients at initial and end time 
in EPO and none EPO users.  
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Figure (9): The difference in Hb status in EPO users and none users at  
times 1 and 2 in ESRD             n = 35 
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Table (11): Hb status in Pre-ESRD patients, EPO users and none users, at 
Zero time and End time: 
 
Correlation P-
value 
T-
value 
CV Std.Dev. +% Mean N Status EPO
0.0 0.0 8 1 Zero time  
 
 
 
 
 0.0 0.0 
 
 10 1 End time 
 
          
21. 8 1.72 7.87 3 Zero time  
 
 
 
 
 4.06 0.37
 
 9.33 3 End time 
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? Hematocrit status before and after EPO in ESRD patients: 
Of the twenty five patients who used EPO the initial hematocrit had a mean 
of 23.628 % ± 6.87 SD and the final hematocrit had a mean of 23.196 % 
±3.68 SD (P=0.517).The CV was 29.09 and 15.88 for Zero-time and End-
time respectively, and the correlation =0.517.  
 Of the ten patients who used EPO the initial hematocrit had a mean of 
25.26 % ± 5.25 SD and the final hematocrit had a mean of 25.24 % ±7.5 
SD (P=0.995).The CVs were 20.77,and 29.72 at times 1 and 2 respectively 
(the correlation =-0.35).Figure (10) shows these findings. 
Hematocrit status before and after EPO in pre-ESRD patients: 
The hematocrit in the patient who received EPO was initially found to be 
24.7 % and at End-time became 31.4 %, while in the three who didn't 
receive it the mean hematocrit was 22.87± 5.68 SD at Zero-time and 28.7 ± 
1.99 SD at End-time (P=0.119), Table (12). 
3.4.3 Investigations for evaluation of the iron status of the patients: 
In a total of fifty three patients investigated at commencement of the study, 
the mean serum iron level was found to be 99.97 µg/dl ± 78.39 SD at Zero-
time and 94.05 µg/dl ± 79.24 SD at End-time. 
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Figure (10): HCT status at Zero-time and End-time in ESRD, EPO users 
and non-use 
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Table (12) HCT status for pre-ESRD patients, EPO users and none users, 
at Zero and End-time: 
 
Correlati
on 
P-
value 
T-
valu
e 
CV Std.Dev. +% Mea
n 
N Status EPO 
0.0 0.0 24.7 1 Zero time  
 
 
 
 
 0.0 0.0 
 
 31.4 1 End time 
 
          
24.
8 5.68 
22.8
7 3 
T 
   
6.8
6 1.99 
 
 
28.7 3 
Time 2  
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Among those who were investigated at both zero and End-time, evaluation 
was carried out statistically in users and none users of EPO, their number 
was thirty one patients, twenty three (74 %) used EPO, and the remaining 
eight (26 %) didn't. 
Serum iron: 
In the two ESRD patients who used EPO, the mean serum iron levels at 
Zero-time and End-time were 95.91 µg/dl ±  76.46 SD and 104.39µg/dl ± 
91.89  SD respectively (P=0.748), and the rate of changes was 8.84 %.The 
correlation was -0.093. 
For the EPO none user ESRD patients the mean serum iron levels at time 
Zero-time and End-time were 89.75 µg/dl ±  60.19 SD and 86 µg/dl ± 65.14  
SD respectively (P=0.904), and the rate of change was -4.18 % %.The 
correlation was 0.087. 
In the three pre-ESRD patients who used EPO, the mean serum iron levels 
at Zero-time and end time were 15 µg/dl ± 1.41  SD and 49 µg/dl ± 21.21  
SD respectively (P=0.249), and the rate of change was 226.7 %.The 
correlation was 1.0. 
In pre-ESRD patients who did not use EPO, the mean serum iron levels at 
Zero-time and End-time were 125 µg/dl ± 87.5  SD and 82.7 µg/dl ± 12.05 
SD respectively (P=0.1), and the rate of change was -33.8 %.The 
correlation was –1.87. 
The differences in serum iron between ESRD and pre-ESRD at zero and 
End-times are shown in Figure (11): 
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Figure(11):Iron levels for ESRD and pre-ERSD; EPO users and non users: 
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Transferrin Saturation (TSAT): 
For the twenty two EPO  user ESRD patients the mean TSAT at Zero-time 
and End-time were 29.49 % ±21.08  SD and 36.31 % ± 30.55  SD 
respectively (P=0.414), and the rate of change was 23.13 %. The 
correlation was found to be - 0.078. 
In the seven pre-ESRD patients who did not use EPO TSAT at Zero-time 
and End-time were found to be 30.59 % ± 15.37 SD and 37.05 % ± 15.37  
SD respectively (P=0.582), and the rate of change was 21.12 %. The 
correlation was found to be - 0.023. 
The change in TSAT of pre and ESRD patients is shown in Figure (12). 
Serum ferritin: 
The mean serum ferritin for the patients at zero time was 252.72 ng/dl 
±200.69 SD, and at end time 360.83 ng/dl ± 210.99 SD . 
Thirty two patients were evaluated for differences in ferritin in the ESRD 
group, and five were evaluated in the pre- ESRD group. 
In ESRD patients who used EPO , the mean ferritin was 1011.65 ng/dl ± 
431.31 SD  and 1074.93 ng/dl ± 344.82 SD  at Zero-time and End-time 
respectively (P=0.44) ,and the rate of change = 6.26 %. 
In  ESRD patients who did not use EPO , the mean ferritin was 729 ng/dl ± 
537.2 SD  and 1108 ng/dl ± 191.86 SD  at Zero-time and End-time 
respectively (P=0.041)* ,and the rate of change = 51.8 %. 
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Figure (12): TSAT in ESRD and pre-ESRD; EPO and none EPO users: 
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Ferritin levels in pre-ESRD in users and none user of EPO: 
The mean serum ferritin at Zero Zero-time and End-time in EPO users 
decreased from 501.39 ± 603 SD to 382.02 ± 462 SD. This was 
insignificant (p=0.442), and none users showed a decrease from 1100.43 ± 
130 SD to 940.83 ng/dl ± 515 SD which was also not significant (P = 0.55), 
as shown in Figure (13). 
Those who received EPO had some what a static level at End-time 
,whereas the EPO none users experienced an increase in ferritin level at 
End-time. The difference in ferritin levels in Zero-time and End-time in 
ESRD as compared to pre-ESRD patients is shown in Figure (14) 
3.3.7 The outcome function: 
The outcome (deaths) of patients in the study group was assessed. The 
MDA has been applied for the outcome. In the ANOVA table below, the 
smaller the Wilks's lambda, the more important the independent variable to 
the discriminant function. Wilks's lambda is significant by the F test for 
history of blood transfusion, type of dialysis, absence of  iron dextran, and 
erythropoieth (since the p-value <0.05). All other remaining variables are 
not significant, Table(13). 
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Figure(13):Ferritin Levels for ESRD and pre-ESRD; EPO non-users                                    
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Figure (14): Ferritin levels for ESRD and Pre-ESRD at Zero time – End-time using EPO 
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Table (13): Tests of Equality of Group Means 
Variables 
Wilks' 
Lambda F Sig. 
GENDER 0.974 0.684 0.416 
ORIGIN 0.954 1.262 0.271 
SOCIOECONOMIC  
STATUS 0.983 0.442 0.512 
DISTRIBUTION  BY  AGE 0.956 1.2 0.283 
LEVEL OF PATERNAL 
EDUCATION 0.975 0.656 0.425 
FREQUENCY OF BLOOD  
TRANSFUSION 0.838 5.041 0.033 
DIALYSIS .   
TYPE OF DIALYSIS 0.808 6.19 0.02 
IRON- RICH  FOODS 0.911 2.532 0.124 
ORAL  IRON  AND NO IRON 0.808 6.19 0.02 
IRON DEXTRAN 0.911 2.532 0.124 
ERYTHROPOIETH 0.808 6.19 0.02 
Hb1 0.88 3.56 0.07 
HCT1 0.92 2.258 0.145 
WBC1 0.948 1.426 0.243 
PLATELETS1 0.984 0.42 0.523 
STAGE OF CRF 0.991 0.242 0.627 
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Outcome and positive history of blood transfusion: 
Among those who received more than 5 blood transfusions during the last 
year, 100% of the risk occurred (2 patients). The Chi-square is 5.10 with a 
p-value of 0.024 indicating a significant result at 5%. Table (14) shows 
relationship between outcome and blood transfusion. 
Outcome and type of dialysis: 
Among the forty one patients receiving dialysis , no death was reported in 
the hemodialysis patients. All nine patients who died were dialysed 
peritoneally. This is highly significant (p=0.00) .Table (15) shows 
relationship between outcome and blood transfusion. The Chi-square is 
5.10 with a p-value of 0.024 indicating a significant result at 5%.  
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Table (14): Distribution of outcome and blood transfusion per year 
Outcome 
 
 Alive % Dead % Total % X2 
P-
value
<5 24 75.0 0 0.0 24 70.6 
>5 8 25.0 2 100.0 10 29.4 
  
Total 32 100 2 0 34 100 5.1 0.024
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Table (15): Distribution of outcome and type of dialysis 
Outcome  
 
 
Aliv
e % Dead % 
To
tal % X2 
P-
value 
Peritoneal 9 28.1 9 100 18 43.9 
Hemo 23 71.9 0 0 23 56.1 
  
Total 32 100 9 100 41 100 5.1 0.024 
*indicates significant result at 5%. 
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Distribution of outcome and iron supplementation: 
Only one patient receiving iron dextran during the study died (11.1%) 
whereas 88.9% of deaths occurred in children who either received oral iron 
supplementation or no supplementation at all, as shown in Table (16). 
Outcome and erythropoietin: 
Eight (88.9%) of the nine deaths occurred during the study was in the 
group of EPO non-users. This was proved highly significant (P = 0.002), 
Table (17). 
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Table (16): Distribution of outcome and receiving iron dextran 
Outcome  
 
 Alive % Dead % Total % X2 P-value
 No Iron 
dextran 20 52.6 8 88.9 28 59.6 
 Iron dextran 18 47.4 1 11.1 19 40.4 
  
Total 38 100 9 100 47 100   
*indicates significant result at 5%. 
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Table (17): Distribution of outcome and receiving EPO 
Outcome  
 
 Alive % Dead % Total % X2 P-value
 Yes 26 68.4 1 11.1 27 57.4 
 No 12 31.6 8 88.9 20 42.6 
  
Total 38 100 9 100 47 100  0.002 
*indicates significant result at 5%. 
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4. DISCUSSION, CONCLSIONS AND RECOMMENDATIONS 
 
4.1 Discussion 
Since anaemia is a major determinant of morbidity in chronic renal 
failure, and as blood transfusions are now a major hazard in general and 
especially in CRF children awaiting renal transplantation, this study was 
designed to evaluate the current management practices and to help 
improve services offered to children with CRF. 
Fifty three CRF paediatric patients were included in this study, all 
were anaemic, and most of them had received blood transfusions in the 
course of their disease. Erythropoetin (Eprex) was received by almost half 
the study group, most of whom were on maintenance hemodialysis, and 
receiving iron dextran concomitantly with intravenous Eprex. 
 The commonest age group seen was the older age group from ten to 
eighteen years, which accounted for nearly three quarters of the patients. 
This is comparable to the age group of children studied by Aufricht C. et al 
the mean age group of the 25 children studied was 15.8+/- 4.2 years (70).  
This observation could be explained by earlier deaths of the younger 
patients even before being diagnosed, because in many occasions the 
condition is missed until patients are much older, or not properly addressed 
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until the condition culminates in CRF. 
Most of the patients were males; making up almost two thirds of the 
study group, this was in contradistinction to the number of males in the 
study by Aufricht-C etal which was less than 50% (7o). 
More than half the children come from the central regions, and this 
could be due to easier access to the renal centers in Khartoum and /or 
more awareness. Families from other regions have problems of late 
diagnosis, less access and financial burden. This assumption is further 
supported by analysis of the socioeconomic status of this study group, 
which showed that almost all the families were of low socioeconomic status 
and therefore can not overcome the obstacles they face in seeking 
services. 
Weight for Age, and Height For Age were both significantly affected 
as shown by mean Z- Scores for the studied group .This reflected 
moderate malnutrition and stunting due to chronic illness as well as poor 
feeding associated with anaemia. 
 Approximately three quarters of the patients had ESRD. The much 
smaller number of patients with pre-ESRD was further decreased towards 
the end -time of the study when most of the patients in this group failed to 
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show for follow up and were therefore lost to the study. More than half of 
the ESRD patients received hemodialysis and this was clearly the main 
factor accounting for better follow up and validity of statistical results in this 
group. 
 A positive history of blood transfusions was encountered in more than 
three quarters of the group, and blood loss was mostly not related to 
dialysis. 
Anaemia was found in all patients with a mean Hb of 7.8 g/dl ± 2.1 
SD, this was in accordance with findings reported by Rigden SP et al 
(67)1990 and Dimitrikov et al (66)1994. 
Reduction in MCH as compared to other indices was the most 
prevalent (90.5%) in accordance with another study in Sudan by Bafakeer 
S. who found low MCH in all children studied (89), this proves that MCH is 
the most sensitive red blood cell indices to change in anaemic patients. 
Platelet counts were normal in all patients, these showed no changes 
at end -time which was consistent with the findings reported by Vinhas J et 
al (78). The fall in hemoglobin which occurred here was also reported by 
Pela in the group of EPO users. Despite the fact that there was a better 
response in the Hb for the group receiving EPO compared with patients not 
on EPO, a slight decline in haemoglobin at end -time rather than 
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improvement was encountered, this decline was proved insignificant 
statistically and we could therefore conclude that there was no change 
brought about by EPO use. This is in contradistinction with the mentioned 
study by Rigden et al where during the course of treatment with EPO the 
Hb in patients had increased significantly (67). Haemoglobin in the pre-
ESRD gave better readings after using EPO, albeit there was only one 
patient in this group. This result could be related to the inadequate doses of 
EPO being given to our patients compared to other studies but also 
because these patients had no support in providing the EPO like the other 
group of pre-ESRD, and as for the more fortunate group of ESRD the 
supply by the donating companies was discontinued several times. In most 
of the previous  studies by Rigden et al (67), Akizawa et al (68) and Van-
Damme (69)  where the hemoglobins reached the target levels , the doses of 
EPO were either titrated depending on response (Dimitricov et al 
(66),Rigden et al (67)and Akizawa et al (68)), given according to weight being 
<or> than 30 gms (Van-Damme L et al (69)),administered in three different 
doses (Aufricht et al (70)),or as in the study by Dimitrikov (66) the EPO dose 
were escalated as well as given subcutaneously thrice weekly. Patients in 
this study received EPO in a fixed dose of 100 U/kg per week, and only 
those on hemodialysis received it on regular basis. 
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The differences in hematocrits of ESRD patients at zero-time as 
compared to End- time were evaluated in EPO users and none users, and 
results showed that there was no significant difference in HCT at End- time 
contrary to results by Litwin M et al(65)who reported an increase in 
hematocrit. This result could be explained by the small, untitrated doses of 
EPO, or as concluded by Aufricht et al (70), the small starting doses which 
he proved to be linearly related to increases in HCT. In those who didn't 
use EPO there was no difference at all.  
In pre-ESRD patients HCTs increased in both EPO users and none 
users, but results were none conclusive because of the small number of 
patients and were therefore proved statistically insignificant. 
The iron status in ESRD patients who used EPO was normal at zero- 
time in contrast to that found by Shaheen et al (87), where iron was low in 
more than 50% of patients prior to commencement of treatment, but was 
consistent with Tammam Ahmed findings (75). Levels at end time did not 
change significantly, a finding also found by Pela et al (78).  
Similar results were arrived at with transferrin saturation which also 
showed no change related to EPO use, in contradistinction to reports by 
Pela et al (78), Litwi M et al (65)and Shaheen et al (87), all of whom reported 
reductions in transferrin saturations.. It was noticed that the iron levels of 
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some of the patients on hemodialysis were high, this contributed to the final 
mean being in the normal range. Revision of these patients revealed that 
some of the smaller patients received high doses of intravenous iron 
dextran per weight. 
 In the group of ESRD those who received EPO had some what a 
static level of ferritin at end -time, whereas the EPO none users 
experienced an increase in ferritin level at End –time, this could be 
explained by recurrent infections as reported by Pela et al (78), but may as 
well be due to the higher doses of Iron being administered. 
 Judging by results of iron studies which were normal throughout the 
period of the study, and considering the fact that the use of erythropoietin 
did not improve the anaemic status of the patients who received it; we 
could assume that iron deficiency was not implicated in this result , yet 
functional iron deficiency  could not be ruled out.  
 The mortality in both groups of patients by the end of the study was 
tested statistically for dependent variables that could have influence in the 
results and outcome. Four variables proved significant; namely, frequency 
of blood transfusion being >5 per year, Iron being administered orally as 
compared to parantaraly, being on hemodialysis, and receiving 
erythropoietin treatments. The last two factors had a favourable influence 
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on outcome in contradistinction to the first two. 
 It became clear from this that the better outcome encountered in the 
group of ESRD was mainly due to better medical care and EPO offered to 
those on regular hemodialysis despite their worse renal functions which 
seemed to have played a major role in slowing the deterioration that 
otherwise would have occurred and prolonged survival .This was formerly 
proved by studies of Lim et al (60), Jungers et al (61),Kramer et al (62) and 
Mihaly Tapolyai et al  (64). 
 The other observation was that almost all of these patients had no 
reasonable chance or plans for renal transplantation, which raises an 
interesting issue of unwise utilization of the limited resources to the wrong 
group of patients. 
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4.2 Conclusions: 
1 Anaemia was universal in the study group. 
2 The patients with CRF most encountered were males ten to eighteen 
years old. 
3 Failure of early diagnosis and management of renal diseases were 
perceived as the major factor in reaching ESRD in Sudanese children. 
4 Medical treatment for anaemia was not adjusted in dose, route or mode 
of administration leading to inadequate response to treatment with EPO. 
5 Although erythropoietin was not administered properly, yet it played a 
significant role in preserving the haemoglobins and hematocrits of the 
patients who used it.  
6 Iron deficiency was ruled out as a cause of hyporesponsiveness to 
erythropoietin therapy. 
7 Iron therapy given concomitantly with EPO was not monitored in some 
hemodialyzed patients. 
8 The worst outcome was that among pre-ESRD rather than ESRD 
patients. 
9 Predictors of mortality In the study group were found to be: type of 
dialysis being peritoneal rather than hemodialysis, receiving more 
frequent blood transfusions, having iron introduced orally rather than 
intravenously, and not using erythropoietin for management of anaemia. 
 
96 
 
4.32 Recommendations: 
1 More emphasis and better training of medical staffs about anaemia 
management in the pre-ESRD patients. 
2 Substitution of erythropoietin for blood transfusion whenever it can be 
avoided. 
3 Protocols for anaemia management with individualized treatment 
options. 
4 Promotion of renal centers to establish better follow up services, and 
more accessible services to patients in out-reach areas. 
5 Further studies on a larger scope to promote the medical services in 
renal centers. 
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